Unknown

Dataset Information

0

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells.


ABSTRACT: Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority. Here, we studied the mechanism of action of the isomers trans and cis-[PtI2(isopropylamine)2] (I5 and I6, respectively) against gastrointestinal cancer cells. We demonstrate that I5 and I6 modulate mitochondrial metabolism, decreasing OXPHOS activity and negatively affecting ATP-linked oxygen consumption rate. Consequently, I5 and I6 generated Reactive Oxygen Species (ROS), provoking oxidative damage and eventually the induction of senescence. Thus, herein we propose a loop with three interconnected processes modulated by these iodido agents: (i) mitochondrial dysfunction and metabolic disruptions; (ii) ROS generation and oxidative damage; and (iii) cellular senescence. Functionally, I5 reduces cancer cell clonogenicity and tumor growth in a pancreatic xenograft model without systemic toxicity, highlighting a potential anticancer complex that warrants additional pre-clinical studies.

SUBMITTER: Melones-Herrero J 

PROVIDER: S-EPMC10959927 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells.

Melones-Herrero Jorge J   Alcalá Sonia S   Ruiz-Cañas Laura L   Benítez-Buelga Carlos C   Batres-Ramos Sandra S   Calés Carmela C   Lorenzo Oscar O   Perona Rosario R   Quiroga Adoración G AG   Sainz Bruno B   Sánchez-Pérez Isabel I  

Communications biology 20240322 1


Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority. Here, we studied the mechanism of action of the isomers trans and cis-[PtI<sub>2</sub>(isopropylamine)<sub>2</sub>] (I5 and I6, respectively) against gastrointestinal cancer cells. We demonstrate that I5 and I6 modulate mitochondrial metabolism, decreasing OXPHOS  ...[more]

Similar Datasets

| S-EPMC3089208 | biostudies-literature
| S-EPMC9525650 | biostudies-literature
| S-EPMC2891414 | biostudies-literature
| S-EPMC11012213 | biostudies-literature
| S-EPMC11772088 | biostudies-literature
| S-EPMC2969087 | biostudies-literature
| S-EPMC10231978 | biostudies-literature
| S-EPMC5974149 | biostudies-literature
2007-04-19 | GSE7035 | GEO
| S-EPMC4318771 | biostudies-literature